How much does the third-generation targeted drug Osimertinib (Tagrisso) cost?

Osimertinib is a third-generation targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC), especially those with advanced NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations. Osimertinib is already on the market in China and has been included in medical insurance. Patients can purchase it at domestic hospital pharmacies. Below is price information about osimertinib:

1.Domestic price:

in the country, osimertinib is an imported original drug and its price is relatively high. According to the pricing strategies of different regions and different hospitals, the price of osimertinib is about four to five thousand yuan. However, specific prices may fluctuate, and patients can consult their local hospital pharmacy for the latest price information.

2.Medical insurance reimbursement:

Osimertinib has been included in the national medical insurance catalog, so eligible patients can enjoy medical insurance reimbursement. Medical insurance reimbursement policies may vary by region, and patients should consult their local hospital pharmacy for specific policies and requirements regarding medical insurance reimbursement. Under normal circumstances, medical insurance reimbursement can effectively reduce the financial burden of patients and make it easier for patients to obtain the drugs they need for treatment.

3.Comparison of foreign generic drug prices:

Although the domestic price of osimertinib is relatively high, there are some generic drugs of osimertinib abroad, such as the Lao version and the Bangladeshi version. The price of these generic drugs is much cheaper than the domestic original drugs, about a few hundred yuan. Although the price is lower, patients need to pay attention to the source and quality of the drug when choosing to purchase it, and ensure the effectiveness and safety of the drug.

Osimertinib is a targeted therapy drug in the treatment ofEGFRmutation-positive advanced stageNSCLCThe patients showed significant results. Although the price is higher, the policy of inclusion in medical insurance and the supply network of the domestic drug market provide patients with more convenient and economical purchasing channels. Ultimately, patients can choose the appropriate way to purchase drugs based on their own circumstances and financial capabilities, and follow the doctor's recommendations for treatment.